Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

NCT06725758 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.

NCT NCT06725758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06725758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Lead sponsor
Orion Corporation, Orion Pharma
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 26, 2023
Completion date
December 31, 2027
Enrollment
315 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours